Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S (ASND)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/15/2018 02/16/2018 02/20/2018 02/21/2018 02/22/2018 Date
55.79(c) 55.81(c) 59(c) 58(c) 59.43(c) Last
341 236 74 976 101 982 322 520 1 757 189 Volume
-0.38% +0.04% +5.72% -1.69% +2.47% Change
More quotes
Financials (€)
Sales 2017 1,77 M
EBIT 2017 -110 M
Net income 2017 -120 M
Finance 2017 183 M
Yield 2017 -
Sales 2018 2,09 M
EBIT 2018 -128 M
Net income 2018 -131 M
Finance 2018 172 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 867x
EV / Sales2018 739x
Capitalization 1 717 M
More Financials
Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates.Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs.The company was founded by Jan Møller Mikkelsen in... 
More about the company
Surperformance© ratings of Ascendis Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ASCENDIS PHARMA A/S
05:46aAscendis Pharma A/S Announces Pricing of Public Offering of ADSs
GL
02/21ASCENDIS PHARMA A/S : Announces Proposed Public Offering of ADSs
AQ
02/20Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
GL
02/12ASCENDIS PHARMA A/S : Announces Participation in Leerink Partners 7th Annual Glo..
AQ
02/08Ascendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Gl..
GL
01/09ASCENDIS PHARMA A/S : Provides Update on Rare Disease Endocrinology Pipeline and..
AQ
01/08Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Pr..
GL
01/03Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of..
GL
2017ASCENDIS PHARMA A/S : A S Announces Participation in 36th Annual J.P. Morgan Hea..
AQ
2017Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Health..
GL
More news
Sector news : Bio Therapeutic Drugs
04:22pSangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:56pAscendis prices ADS offering at $57  
12:45p$ASND: Ascendis Pharma prices 3,947,368 ADSs at $57.00 per share  
12:27pAscendis Pharma A/S $ASND Upgraded to “Hold” by Zacks Investment Research  
07:09aAscendis Pharma A/S Announces Pricing of Public Offering of ADSs  
06:02aBRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per AD.. 
More tweets
Qtime:97
News from SeekingAlpha
06:56aAscendis prices ADS offering at $57 
02/21ROTY EDITION 1 VOLUME 81 : We Have A Launch Date! 
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Ascendis Pharma launches $150M equity offering 
02/09Key healthcare events next week (continued) 
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | ASND | US04351P1012 | 4-Traders
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 45,4 €
Spread / Average Target -4,0%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, Chief Executive Officer & Director
Mark Peter Brennan Executive Chairman
Neil T. Ringdahl Chief Operating Officer
Scott T. Smith Chief Financial Officer & Senior Vice President
Harald Rau Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S44.78%2 106
GILEAD SCIENCES12.98%105 375
VERTEX PHARMACEUTICALS7.42%39 931
REGENERON PHARMACEUTICALS-14.08%34 113
BIOVERATIV INC92.71%11 232
GENMAB-0.97%10 271